Chiropractors in Sturgis, KY Accepting Medicare
3 Chiropractors found. Showing 1 - 3
 Jeremy R Baker, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 412 N Main St, Sturgis, KY 42459 Phone: 270-333-4641 Fax: 270-333-4641 |
 Kathryn Elizabeth Baker, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 412 Main St, Sturgis, KY 42459 Phone: 270-333-4641 Fax: 270-333-4641 |
 Baker Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 412 N Main St, Sturgis, KY 42459 Phone: 270-333-4641 Fax: 270-333-4641 |
News Archive
Vitamin A-enriched cattle fodder is the key to protect against cow's milk allergy
A real milk allergy occurs in about three to five percent of European children and more rarely in adults. The disease is different from lactose intolerance, in which a lack of the enzyme lactase results in the inability to properly break down lactose, a sugar found in milk products.
GeoVax expands Phase 2a clinical trial for MVA62B HIV/AIDS vaccine
GeoVax Labs, Inc., announced today the expansion of the Phase 2a clinical trial testing of its HIV/AIDS vaccine products. The expanded Phase 2a trial will test the administration of three doses of the recombinant poxvirus vaccine MVA62B without the use of the recombinant DNA-vectored vaccine, which was used to prime immune responses in the first part of this trial.
Personal approach to psychological well-being
At the World Congress on Psychosomatic Medicine in Torino, Italy, Carol Ryff, Professor of Psychology at the University of Wisconsin, has described how, more than simply feeling happy, it is the personal approach to psychological well-being that matters.
Wolverine Venture Fund participates in $8M series A round of financing for Delphinus Medical Technologies
The Wolverine Venture Fund (WVF), managed by The Samuel Zell & Robert H. Lurie Institute for Entrepreneurial Studies at the University of Michigan Ross School of Business, today announced participation in an $8 million series A round of financing for Delphinus Medical Technologies, Inc.
Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia
Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla.
› Verified 2 days ago